Akeso (HKG:9926) and Summit Therapeutics suffered a setback after less favorable clinical data for its ivonescimab lung cancer drug diminished hopes for approval, the South China Morning Post reported Monday.
The US Food and Drug Administration indicated a "statistically significant" overall survival benefit, from start of treatment to death, not just delayed tumor progression, is needed for US approval, the report said, citing Summit.
The drug showed progression-free survival but had not yet shown a good enough survival benefit for patients in its study for US approval, the report said.
Shares in Akeso jumped 7% during afternoon trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.